目的:探讨缬沙坦对自发高血压大鼠(SHR)左室肥厚心肌Kv4.2表达的影响。方法:将16只10周龄雄性SHR随机分成缬沙坦组和非缬沙坦组各8只:8只10周龄Wistar-Kyoto大鼠为对照组。喂药8周后分别测定各组大鼠动脉收缩压、左室质量指数(LVMI)、...目的:探讨缬沙坦对自发高血压大鼠(SHR)左室肥厚心肌Kv4.2表达的影响。方法:将16只10周龄雄性SHR随机分成缬沙坦组和非缬沙坦组各8只:8只10周龄Wistar-Kyoto大鼠为对照组。喂药8周后分别测定各组大鼠动脉收缩压、左室质量指数(LVMI)、左室心肌Kv4.2的表达。结果:非缬沙坦组和缬沙坦组LVMI明显大于对照组(3.7+0.02 mg/g and 3.2-0.03mg/g vs 2.5±0.03mg/g,P<0.0叭),非缬沙坦组LVMI明显大于缬沙坦组(3.7±+0.02 mg/g vs 3.2+0.03 mg/g,P<0.001);非缬沙坦组和缬沙坦组左心室心肌Kv4.2表达明显低于对照组(P<0.01),缬沙坦组左心室心肌Kv4.2的表达明显高于非缬沙坦组(P<0.01)。结论:缬沙坦通过逆转SHR左室心肌肥厚提高左室心肌Kv4.2的表达。展开更多
Genome-wide studies have reported that Parkinson’s disease is associated with abnormal expression of various growth factors. In this study, male C57 BL/6 mice aged 10 weeks were used to establish Parkinson’s disease...Genome-wide studies have reported that Parkinson’s disease is associated with abnormal expression of various growth factors. In this study, male C57 BL/6 mice aged 10 weeks were used to establish Parkinson’s disease models using an intraperitoneal injection of 60 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 28 days later, 10 or 100 ng fibroblast growth factor 20 was injected intracerebroventricularly. The electrophysiological changes in the mouse hippocampus were recorded using a full-cell patch clamp. Expression of Kv4.2 in the substantia nigra was analyzed using a western blot assay. Serum malondialdehyde levels were analyzed by enzyme-linked immunosorbent assay. The motor coordination of mice was evaluated using the rotarod test. The results showed that fibroblast growth factor 20 decreased A-type potassium current in neurons of the substantia nigra, increased long-term potentiation amplitude in the hippocampus, and downregulated Kv4.2 expression. A high dose of fibroblast growth factor 20 reduced serum malondialdehyde levels and enhanced the motor coordination of mice. These findings confirm that fibroblast growth factor 20 has a therapeutic effect on the toxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and its mechanism of action is associated with the inhibition of A-type K+ currents and Kv4.2 expression. All animal procedures were approved by the Animal Care and Use Committee of Qilu Hospital of Shandong University, China in 2017(approval No. KYLL-2017-0012).展开更多
基金This work was supported by the National Basic Research Priorities Programme of China (No. 1998051106) National High TECH Research and Development Programme of China ( No. 2001AA234021).
文摘目的:探讨缬沙坦对自发高血压大鼠(SHR)左室肥厚心肌Kv4.2表达的影响。方法:将16只10周龄雄性SHR随机分成缬沙坦组和非缬沙坦组各8只:8只10周龄Wistar-Kyoto大鼠为对照组。喂药8周后分别测定各组大鼠动脉收缩压、左室质量指数(LVMI)、左室心肌Kv4.2的表达。结果:非缬沙坦组和缬沙坦组LVMI明显大于对照组(3.7+0.02 mg/g and 3.2-0.03mg/g vs 2.5±0.03mg/g,P<0.0叭),非缬沙坦组LVMI明显大于缬沙坦组(3.7±+0.02 mg/g vs 3.2+0.03 mg/g,P<0.001);非缬沙坦组和缬沙坦组左心室心肌Kv4.2表达明显低于对照组(P<0.01),缬沙坦组左心室心肌Kv4.2的表达明显高于非缬沙坦组(P<0.01)。结论:缬沙坦通过逆转SHR左室心肌肥厚提高左室心肌Kv4.2的表达。
文摘Genome-wide studies have reported that Parkinson’s disease is associated with abnormal expression of various growth factors. In this study, male C57 BL/6 mice aged 10 weeks were used to establish Parkinson’s disease models using an intraperitoneal injection of 60 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 28 days later, 10 or 100 ng fibroblast growth factor 20 was injected intracerebroventricularly. The electrophysiological changes in the mouse hippocampus were recorded using a full-cell patch clamp. Expression of Kv4.2 in the substantia nigra was analyzed using a western blot assay. Serum malondialdehyde levels were analyzed by enzyme-linked immunosorbent assay. The motor coordination of mice was evaluated using the rotarod test. The results showed that fibroblast growth factor 20 decreased A-type potassium current in neurons of the substantia nigra, increased long-term potentiation amplitude in the hippocampus, and downregulated Kv4.2 expression. A high dose of fibroblast growth factor 20 reduced serum malondialdehyde levels and enhanced the motor coordination of mice. These findings confirm that fibroblast growth factor 20 has a therapeutic effect on the toxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and its mechanism of action is associated with the inhibition of A-type K+ currents and Kv4.2 expression. All animal procedures were approved by the Animal Care and Use Committee of Qilu Hospital of Shandong University, China in 2017(approval No. KYLL-2017-0012).
